002252 上海莱士
已收盘 10-09 15:00:00
资讯
新帖
简况
上海莱士(002252)10月8日主力资金净卖出6243.45万元
证券之星 · 09:17
上海莱士(002252)10月8日主力资金净卖出6243.45万元
上海莱士(002252)9月30日主力资金净卖出2047.54万元
证券之星 · 10-08 09:07
上海莱士(002252)9月30日主力资金净卖出2047.54万元
股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》
证券之星 · 10-08 00:59
股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》
上海莱士收购BI生产基地:工厂易手,行业换挡
同花顺 · 09-29
上海莱士收购BI生产基地:工厂易手,行业换挡
上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力
格隆汇 · 09-29
上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力
上海莱士(002252)9月28日主力资金净买入1209.55万元
证券之星 · 09-29
上海莱士(002252)9月28日主力资金净买入1209.55万元
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
证券之星 · 09-28
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
上海莱士:9月24日公司首次回购股份10880400股
证券日报 · 09-27
上海莱士:9月24日公司首次回购股份10880400股
全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?
新浪证券 · 09-24
全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
证券之星 · 09-24
股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》
上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权
智通财经 · 09-23
上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权
公司问答丨上海莱士:相关说法为海外媒体市场传闻 目前并无官方落地安排
格隆汇 · 09-23
公司问答丨上海莱士:相关说法为海外媒体市场传闻 目前并无官方落地安排
上海莱士(002252.SZ)子公司获人纤维蛋白原药品注册证书
智通财经 · 09-18
上海莱士(002252.SZ)子公司获人纤维蛋白原药品注册证书
上海莱士:全资子公司获人纤维蛋白原药品注册证书
格隆汇 · 09-18
上海莱士:全资子公司获人纤维蛋白原药品注册证书
上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验
智通财经 · 09-16
上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验
上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%
证券之星 · 09-16
上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%
股市必读:上海莱士新发布《回购报告书》
证券之星 · 09-11
股市必读:上海莱士新发布《回购报告书》
上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%
证券之星 · 09-10
上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%
上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%
证券之星 · 09-09
上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%
上海莱士:截至2026年8月31日,公司股东总户数为116,589户
证券之星 · 09-09
上海莱士:截至2026年8月31日,公司股东总户数为116,589户
加载更多
公司概况
公司名称:
上海莱士血液制品股份有限公司
所属行业:
医药制造业
上市日期:
2008-06-23
主营业务:
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。
发行价格:
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":5.06,"timestamp":1791529407000,"preClose":5.06,"halted":0,"volume":67982500,"delay":0,"changeRate":0,"floatShares":6588000000,"shares":6593000000,"eps":0.1833,"marketStatus":"已收盘","change":0,"latestTime":"10-09 15:00:00","open":5.05,"high":5.11,"low":5,"amount":345000000,"amplitude":0.0217,"askPrice":5.07,"askSize":487,"bidPrice":5.06,"bidSize":3909,"shortable":0,"etf":0,"ttmEps":0.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.06,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":5.57,"lowLimit":4.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":1.03,"roa":"--","peRate":27.605019,"roe":"2.04%","epsLYR":0.24,"committee":-0.167625,"marketValue":33359000000,"turnoverRate":0.0103,"status":2,"floatMarketCap":33336000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2674215881","title":"上海莱士(002252)10月8日主力资金净卖出6243.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674215881","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674215881?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:17","pubTimestamp":1791508637,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月8日收盘,上海莱士报收于5.06元,下跌4.89%,换手率1.95%,成交量128.59万手,成交额6.63亿元。10月8日的资金流向数据方面,主力资金净流出6243.45万元,占总成交额9.42%,游资资金净流入3485.96万元,占总成交额5.26%,散户资金净流入2757.49万元,占总成交额4.16%。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入8638.73万元,融资偿还4287.34万元,融资净买入4351.38万元。上海莱士主营业务:生产和销售血液制品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","BK0046","002252","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049709","title":"上海莱士(002252)9月30日主力资金净卖出2047.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049709?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:07","pubTimestamp":1791421640,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月30日收盘,上海莱士报收于5.32元,上涨2.9%,换手率1.36%,成交量89.9万手,成交额4.76亿元。9月30日的资金流向数据方面,主力资金净流出2047.54万元,占总成交额4.3%,游资资金净流出336.13万元,占总成交额0.71%,散户资金净流入2383.67万元,占总成交额5.01%。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入4625.14万元,融资偿还5341.1万元,融资净偿还715.96万元。上海莱士主营业务:生产和销售血液制品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0046","002252","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673145090","title":"股市必读:上海莱士新发布《关于第二期员工持股计划实施进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673145090","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673145090?lang=zh_cn&edition=full","pubTime":"2026-10-08 00:59","pubTimestamp":1791392347,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,上海莱士报收于5.32元,上涨2.9%,换手率1.36%,成交量89.9万手,成交额4.76亿元。当日关注点交易信息汇总:9月30日主力资金净流出2047.54万元,占总成交额4.3%。公司公告汇总:第二期员工持股计划证券账户已于2026年9月28日开立,截至9月30日尚未持有公司股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","002252","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671299291","title":"上海莱士收购BI生产基地:工厂易手,行业换挡","url":"https://stock-news.laohu8.com/highlight/detail?id=2671299291","media":"同花顺","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671299291?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:45","pubTimestamp":1790667900,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛近日,上海莱士宣布收购勃林格殷格翰(BI)中国生物药业100%股权,拿下其位于上海张江、具备6000升商业化产能的CDMO基地。这宗交易在生物医药圈引发的讨论热度,远超 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260929/c680359069.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260929/c680359069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","BK0046","BK0188","002252","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671821295","title":"上海莱士回应收购CDMO工厂:意欲补齐创新药产业化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2671821295","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671821295?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:01","pubTimestamp":1790661712,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","002252","BK0239","159992","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671016269","title":"上海莱士(002252)9月28日主力资金净买入1209.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671016269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671016269?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:07","pubTimestamp":1790644055,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月28日收盘,上海莱士报收于5.08元,上涨1.2%,换手率0.98%,成交量64.38万手,成交额3.26亿元。近5日资金流向一览见下表:上海莱士融资融券信息显示,融资方面,当日融资买入2847.78万元,融资偿还4811.08万元,融资净偿还1963.3万元。上海莱士主营业务:生产和销售血液制品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0239","BK0188","BK0028","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409363","title":"股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409363","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409363?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:15","pubTimestamp":1790529311,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,上海莱士报收于5.02元,上涨1.01%,换手率1.23%,成交量80.95万手,成交额4.05亿元。公司公告汇总关于第六届董事会第二十二次(临时)会议决议公告上海莱士第六届董事会第二十二次(临时)会议于2026年9月23日召开,审议通过《关于收购勃林格殷格翰生物药业(中国)有限公司100%股权暨签署〈收购和出售协议〉及其附属协议的议案》,表决结果为11票同意、0票反对、0票弃权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","BK0239","BK0028","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670063304","title":"上海莱士:9月24日公司首次回购股份10880400股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670063304","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670063304?lang=zh_cn&edition=full","pubTime":"2026-09-27 20:40","pubTimestamp":1790512800,"startTime":"0","endTime":"0","summary":"证券日报网讯9月27日,上海莱士发布公告称,2026年9月24日,公司首次通过回购专用证券账户以集中竞价方式回购公司股份,回购公司股份数量为10,880,400股,占公司总股本的0.165%,首次回购股份的最高成交价为5.09元/股,最低成交价为4.93元/股,成交总金额为54,534,487.10元(不含交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-27/doc-inithqpv9321483.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-27/doc-inithqpv9321483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002252","BK0196","BK0046","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669742463","title":"全球首创APC机制挺进III期 上海莱士SR604商业化前景如何?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669742463","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669742463?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239200,"startTime":"0","endTime":"0","summary":"作为全球首个通过抑制APC实现凝血再平衡的血友病治疗药物,SR604属于First-in-class创新品种,结合临床成功率分级标准,Ⅲ期FIC类药物临床成功率取0.40。折现系数方面,上海莱士作为国内成熟的大型血液制品企业,整体经营风险较低,但SR604为First-in-class创新药,当前处于Ⅲ期临床阶段,开发风险高于已成熟的仿制药与生物类似药管线,对应折现率取13%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-24/doc-inisxnuv5181611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","BK0196","002252","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669543870","title":"股市必读:上海莱士新发布《关于第六届董事会第二十二次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669543870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669543870?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:50","pubTimestamp":1790185827,"startTime":"0","endTime":"0","summary":"公司公告汇总关于第六届董事会第二十二次(临时)会议决议公告上海莱士第六届董事会第二十二次(临时)会议于2026年9月23日召开,审议通过《关于收购勃林格殷格翰生物药业(中国)有限公司100%股权暨签署〈收购和出售协议〉及其附属协议的议案》,表决结果为11票同意、0票反对、0票弃权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0239","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669102809","title":"上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2669102809","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669102809?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:43","pubTimestamp":1790156639,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士 发布公告,公司拟以现金方式收购勃林格殷格翰(中国)投资有限公司持有的勃林格殷格翰生物药业(中国)有限公司100%股权,预计收购价格不超过2000万元。交易完成后,标的公司将成为公司全资子公司。标的公司建有生物制药合同生产基地,具备6000L规模商业化生产能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海莱士(002252.SZ)拟收购勃林格殷格翰生物药业100%股权","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002252","BK0196","BK0239","BK0028","BK0046","BK0188","159839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669103000","title":"公司问答丨上海莱士:相关说法为海外媒体市场传闻 目前并无官方落地安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2669103000","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669103000?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:29","pubTimestamp":1790148561,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0196","BK0239","002252","BK0028","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923149","title":"上海莱士(002252.SZ)子公司获人纤维蛋白原药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923149","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668923149?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:06","pubTimestamp":1789733211,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士(002252.SZ)发布公告,公司全资子公司南岳生物制药有限公司(“南岳生物”)于近期收到国家药品监督管理局下发的人纤维蛋白原《药品注册证书》,人纤维蛋白原系由健康人血浆,经分离、提纯,并经病毒去除和灭活处理、冻干制成。南岳生物本产品用于先天性纤维蛋白原减少或缺乏症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海莱士(002252.SZ)子公司获人纤维蛋白原药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0196","002252","BK0188","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668174947","title":"上海莱士:全资子公司获人纤维蛋白原药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668174947","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668174947?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:33","pubTimestamp":1789727603,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","002252","BK0239","BK0046","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988673","title":"上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988673?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:56","pubTimestamp":1789559791,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士 发布公告,公司在研产品“SR604注射液”于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了“血友病A/B患者出血发作的预防治疗”Ⅲ期临床试验登记信息,试验名称:评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性和安全性的单臂、多中心Ⅲ期临床试验试验目的:评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","PSYK","IBBJ","BMED","BK0196","MDTX","BK0046","002252","BK0239","BK0028","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601750","title":"上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667601750?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:36","pubTimestamp":1789551397,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年9月10日公司股东户数为11.63万户,较8月31日减少324.0户,减幅为0.28%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至9月10日,生物制品行业平均股东户数为3.59万户。从股价来看,2026年8月31日至2026年9月10日,上海莱士区间涨幅为2.67%,在此期间股东户数减少324.0户,减幅为0.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600027790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0239","002252","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597722","title":"股市必读:上海莱士新发布《回购报告书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597722","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666597722?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:24","pubTimestamp":1789061054,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,上海莱士报收于5.0元,上涨0.2%,换手率0.56%,成交量36.7万手,成交额1.82亿元。当日关注点交易信息汇总:9月10日主力资金净流入1067.71万元,占总成交额5.86%。公司公告汇总:上海莱士拟以集中竞价方式回购股份,金额2.5亿–5亿元,价格不超7.18元/股,回购股份将用于注销并减少注册资本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0046","002252","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561140","title":"上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561140","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561140?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:31","pubTimestamp":1789032713,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,上海莱士报收于5.0元,较前一交易日上涨0.2%,最新总市值为329.63亿元。该股当日开盘5.01元,最高5.03元,最低4.92元,成交额达1.82亿元,换手率为0.56%。近日,上海莱士披露《回购报告书》。本次回购股份将用于注销并减少注册资本。回购实施期限为自股东会审议通过之日起12个月内。公司已开立回购专用证券账户,相关审议程序已履行完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002252","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058976","title":"上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058976","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666058976?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:27","pubTimestamp":1788946046,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年8月31日公司股东户数为11.66万户,较8月20日减少1411.0户,减幅为1.2%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至8月31日,生物制品行业平均股东户数为3.58万户。从股价来看,2026年8月20日至2026年8月31日,上海莱士区间跌幅为3.18%,在此期间股东户数减少1411.0户,减幅为1.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0196","002252","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666301035","title":"上海莱士:截至2026年8月31日,公司股东总户数为116,589户","url":"https://stock-news.laohu8.com/highlight/detail?id=2666301035","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666301035?lang=zh_cn&edition=full","pubTime":"2026-09-09 11:38","pubTimestamp":1788925084,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止8月31号,公司的股东人数是多少?谢谢上海莱士回复:感谢您的关注! 截至2026年8月31日,公司股东总户数为116,589户。 谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900015217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","BK0046","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791536391301,"stockEarnings":[{"period":"1week","weight":-0.0489},{"period":"1month","weight":0},{"period":"3month","weight":0.1048},{"period":"6month","weight":-0.1121},{"period":"1year","weight":-0.2363},{"period":"ytd","weight":-0.1943}],"compareEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.0326},{"period":"3month","weight":-0.0461},{"period":"6month","weight":-0.0437},{"period":"1year","weight":-0.0183},{"period":"ytd","weight":-0.0395}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"116265人(较上一季度减少0.28%)","perCapita":"56665股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}